A051901

Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed by Lenalidomide and Nivolumab Maintenance in Primary CNS Lymphoma

Status:

OPEN TO ACCRUAL

Trial Type:
Lymphoma, Neurologic
Age Group:
Adults
Phase:

I

NCT Number:

NCT04609046

Contact:

Ollila, Thomas

TOllila@BrownHealth.org